{Reference Type}: Journal Article
{Title}: Cardio-Oncology Recommendations for Pediatric Oncology Patients: An Australian and New Zealand Delphi Consensus.
{Author}: Toro C;Felmingham B;Jessop S;Celermajer DS;Kotecha RS;Govender D;Terese Hanna DM;O'Connor M;Manudhane R;Ayer J;O'Sullivan J;Sullivan M;Costello B;La Gerche A;Walwyn T;Horvath L;Mateos MK;Fulbright J;Jadhav M;Cheung M;Eisenstat D;Elliott DA;Conyers R;
{Journal}: JACC Adv
{Volume}: 1
{Issue}: 5
{Year}: 2022 Dec
暂无{DOI}: 10.1016/j.jacadv.2022.100155
{Abstract}: Cardio-oncology is a new multidisciplinary area of expertise that seeks to pre-emptively and proactively address cardiac complications that emerge during and following cancer therapy. Modern therapies including molecular targeted therapy and immunotherapy have broadened the agents that can cause cardiac sequelae, often with complications arising within days to weeks of therapy. Several international guidelines have been developed for the acute monitoring of cardio-oncology side effects. However, none are specific to pediatrics. We have addressed this gap in the literature by undertaking a rigorous Delphi consensus approach across 11 domains of cardio-oncology care using an Australian and New Zealand expert group. The expert group consisted of pediatric and adult cardiologists and pediatric oncologists. This Delphi consensus provides an approach to perform risk and baseline assessment, screening, and follow-up, specific to the cancer therapeutic. This review is a useful tool for clinicians involved in the cardio-oncology care of pediatric oncology patients.